PMID- 35488603
OWN - NLM
STAT- MEDLINE
DCOM- 20220503
LR  - 20220503
IS  - 0578-1426 (Print)
IS  - 0578-1426 (Linking)
VI  - 61
IP  - 5
DP  - 2022 May 1
TI  - [A single-center retrospective analysis of 100 consecutive cases treated with 
      lenalidomide/bortezomib/dexamethasone in newly diagnosed multiple myeloma].
PG  - 531-536
LID - 10.3760/cma.j.cn112138-20211105-00776 [doi]
AB  - Objective: To investigate the efficacy and safety of lenalidomide combined with 
      bortezomib and dexamethasone (RVD) in patients with newly diagnosed multiple 
      myeloma (NDMM). Methods: A total of 100 consecutive NDMM patients treated with 
      RVD from August 2016 to September 2020 at Peking University People's Hospital 
      were retrospectively analyzed, including response, drug toxicity, follow-up and 
      survival, and subgroup analysis. Results: The median follow-up time was 19.5 
      (2.0-57.0) months. For patients undergoing autologous stem cell transplantation 
      (ASCT) after RVD regimen, the objective response rate (ORR)/complete 
      response+stringent complete response (CR+sCR)/>/=very good partial response (VGPR) 
      rates were 100%, 73.3% (33/45), 95.6% (43/45) respectively. For 54 patients not 
      receiving transplantation, the ORR/CR+sCR/>/=VGPR rates were 79.6% (43/54), 18.5% 
      (10/54), 51.9% (28/54) respectively. As to the survival analysis, 2-year 
      progression free survival (PFS) rates were 84.5% and 70.9% in transplant and 
      non-transplant patients respectively (P=0.102). Two-year overall survival (OS) 
      rates were 100% and 80.8% in transplant and non-transplant patients respectively 
      (P=0.003). The common hematologic adverse events (AEs) were thrombocytopenia 
      (33%) and neutropenia (25%). Abnormal liver function (43%) and peripheral 
      neuropathy (24%) were recognized more as non-hematologic AEs. Conclusion: RVD as 
      front-line regimen has high efficient response rate and acceptable safety in 
      Chinese NDMM patients.
FAU - Wang, W X
AU  - Wang WX
AD  - Department of Hematology, Peking University People's Hospital & Peking University 
      Institute of Hematology, National Clinical Research Center for Hematologic 
      Disease, Beijing 100044, China.
FAU - Bi, J Y
AU  - Bi JY
AD  - Department of Hematology, Peking University People's Hospital & Peking University 
      Institute of Hematology, National Clinical Research Center for Hematologic 
      Disease, Beijing 100044, China.
FAU - Wen, L
AU  - Wen L
AD  - Department of Hematology, Peking University People's Hospital & Peking University 
      Institute of Hematology, National Clinical Research Center for Hematologic 
      Disease, Beijing 100044, China.
FAU - Duan, W B
AU  - Duan WB
AD  - Department of Hematology, Peking University People's Hospital & Peking University 
      Institute of Hematology, National Clinical Research Center for Hematologic 
      Disease, Beijing 100044, China.
FAU - Liu, Y
AU  - Liu Y
AD  - Department of Hematology, Peking University People's Hospital & Peking University 
      Institute of Hematology, National Clinical Research Center for Hematologic 
      Disease, Beijing 100044, China.
FAU - Wang, F R
AU  - Wang FR
AD  - Department of Hematology, Peking University People's Hospital & Peking University 
      Institute of Hematology, National Clinical Research Center for Hematologic 
      Disease, Beijing 100044, China.
FAU - He, Q
AU  - He Q
AD  - Department of Hematology, Peking University People's Hospital & Peking University 
      Institute of Hematology, National Clinical Research Center for Hematologic 
      Disease, Beijing 100044, China.
FAU - Lu, J
AU  - Lu J
AD  - Department of Hematology, Peking University People's Hospital & Peking University 
      Institute of Hematology, National Clinical Research Center for Hematologic 
      Disease, Beijing 100044, China Collaborative Innovation Center of Hematology, 
      Suzhou 215006, China.
LA  - chi
GR  - CFH 2020-2-4082/Capital's Funds for Health Improvement and Research/
PT  - Journal Article
PL  - China
TA  - Zhonghua Nei Ke Za Zhi
JT  - Zhonghua nei ke za zhi
JID - 16210490R
RN  - 69G8BD63PP (Bortezomib)
RN  - 7S5I7G3JQL (Dexamethasone)
RN  - F0P408N6V4 (Lenalidomide)
SB  - IM
MH  - Antineoplastic Combined Chemotherapy Protocols/therapeutic use
MH  - Bortezomib/therapeutic use
MH  - Dexamethasone/therapeutic use
MH  - *Hematopoietic Stem Cell Transplantation
MH  - Humans
MH  - Lenalidomide/therapeutic use
MH  - *Multiple Myeloma/therapy
MH  - Retrospective Studies
MH  - Transplantation, Autologous
EDAT- 2022/05/01 06:00
MHDA- 2022/05/04 06:00
CRDT- 2022/04/30 04:07
PHST- 2022/04/30 04:07 [entrez]
PHST- 2022/05/01 06:00 [pubmed]
PHST- 2022/05/04 06:00 [medline]
AID - 10.3760/cma.j.cn112138-20211105-00776 [doi]
PST - ppublish
SO  - Zhonghua Nei Ke Za Zhi. 2022 May 1;61(5):531-536. doi: 
      10.3760/cma.j.cn112138-20211105-00776.